{"id":13244,"date":"2011-11-18T12:38:45","date_gmt":"2011-11-18T17:38:45","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&#038;p=13244"},"modified":"2011-11-18T12:38:45","modified_gmt":"2011-11-18T17:38:45","slug":"aha-11-roundup","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/11\/18\/aha-11-roundup\/","title":{"rendered":"AHA.11 Roundup"},"content":{"rendered":"<p><em>Whether you were in Orlando for AHA.11 or not, you&#8217;ll want to check out our coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting.<\/em><\/p>\n<p><strong>VIEWS AND ANALYSIS<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/after-saturn-what-role-for-rosuvastatin-after-aim-high-what-future-for-niacin\/\">ROUNDTABLE: After SATURN, What Role for Rosuvastatin? A CardioExchange Panel:<\/a> Steven Nissen, JoAnne Foody, and Roger Blumenthal answer this question: Reading the results of SATURN in light of the impending arrival of generic atorvastatin, what is the appropriate role of rosuvastatin at this point?<\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/pallas-intrigue-what-role-remains-for-dronedarone\/\">ROUNDTABLE: PALLAS Intrigue: What Role Remains for Dronedarone? <\/a>John Mandrola, Eric Prystowsky, and Sanjay Kaul weigh in on PALLAS and the present and future of Multaq.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/voices\/at-aha-the-title-says-it-all\/\">At AHA, the Title Says It All<\/a>: Susan Cheng lists some of the creative abstract and session titles that have caught her eye &#8212; and interest &#8212; thus far at AHA.11.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/voices\/not-just-pomp-and-circumstance\/\">Not Just Pomp and Circumstance<\/a>: According to Susan Cheng, humanity and substance \u2014 not just ceremony \u2014 were to be found at the AHA Opening Session.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/voices\/aha%e2%80%99s-best-kept-secrets\/\">AHA\u2019s Best-Kept Secrets<\/a>: Susan Cheng looks beyond late-breakers and plenary sessions to clue you in on the hidden gems at the AHA conference \u2014 events you shouldn&#8217;t miss, such as the Laennec session.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/interventional\/isar-react-4-bivalirudin-works-great-less-bleeding\/\">ISAR-REACT 4: Bivalirudin Works Great, Less Bleeding<\/a>: Rick Lange offers perspective on the randomized comparison of abciximab plus heparin versus bivalirudin in NSTEMI patients.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/interventional\/transapical-tavr-on-the-ropes-is-it-down-for-the-count\/\">Transapical TAVR on the Ropes: Is It Down for the Count?<\/a> Citing lackluster data on transapical TAVR from the PARTNER substudy and negative results from STACCATO, Rick Lange and David Hillis ask, &#8220;What is the problem? Is it the procedure, the equipment, or the training? Should we stop the fight and throw transapical TAVR out of the ring?&#8221;<\/li>\n<\/ul>\n<p><strong><\/strong><strong>NEWS<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/elevate-timi-56-one-new-piece-of-the-clopidogrel-puzzle\/\">ELEVATE-TIMI 56: One New Piece of the Clopidogrel Puzzle<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/experts-clash-over-aim-high\/\">Experts Clash Over AIM-HIGH<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/hype-aside-hope-for-stem-cell-therapy-may-be-emerging-from-hibernation\/\">Hype Aside, Hope for Stem Cell Therapy May Be Emerging from Hibernation<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/saturn-regression-trial-gorilla-statin-and-statin-king-battle-to-a-draw\/\">SATURN Regression Trial: Gorilla Statin and Statin King Battle to a Draw<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/aim-high-no-benefit-for-niacin-on-top-of-statins\/\">AIM-HIGH: No Benefit for Niacin on Top of Statins<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/pallas-poor-results-for-dronedarone-in-permanent-af\/\">PALLAS: Poor Results for Dronedarone in Permanent AF<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/mi-freee-how-much-do-free-medications-really-cost\/\">MI FREEE: How Much Do Free Medications Really Cost?<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/adopt-fails-to-support-extended-oral-apixaban-in-high-risk-post-discharge-patients\/\">ADOPT Fails to Support Extended Oral Apixaban in High-Risk Post-Discharge Patients<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/atlas-acs-2-timi-51-rivaroxaban-benefits-low-risk-acs-patients\/\">ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/tracer-novel-anticoagulant-vorapaxar-runs-into-trouble-in-acs\/\">TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/controversy-over-cholesterol-testing-for-children\/\">Controversy Over Cholesterol Testing for Children\u00a0<\/a><\/li>\n<\/ul>\n<ul>\n<li><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/tavi-at-tct-enthusiasm-tempered-by-poor-transapical-outcomes\/\">TAVI at TCT: Enthusiasm Tempered by Poor Transapical Outcomes<\/a><\/li>\n<\/ul>\n<p><strong>THE FELLOWS&#8217; PERSPECTIVE<\/strong><\/p>\n<p>Four of our fellows &#8212; Revathi Balakrishnan, Eiman Jahangir, John Ryan, and Amit Shah &#8212; shared their learning from and experiences of AHA.11:<\/p>\n<ul>\n<li><a href=\"..\/fellowship-training\/evacetrapib-%e2%80%93-the-new-wonder-drug\/\">Evacetrapib \u2013 The New Wonder Drug?<\/a> Drugs that increase HDL have failed to prove utility above statins alone. The pressure is now on evacetrapib to hit the game winning home run.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/was-aim-high-a-hit-or-a-miss\/\">Was AIM HIGH a Hit or a Miss?<\/a> One of the best parts of AHA was the opportunity to hear experts on the panels dissect and interpret the data from a controversial trial.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/aha-lessons-on-emotions-and-heart-disease-depressing-data-but-hopeful-trends\/\">AHA Lessons on Emotions and Heart Disease: Depressing Data but Hopeful Trends<\/a>: The many AHA sessions devoted to depression and heart disease gave renewed focus and drive to this researcher into the psychosocial factors of cardiovascular disease.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/power-to-the-people\/\">POWER to the People<\/a>: Two key lessons derived from this weight-loss study.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/an-event-not-a-conference\/\">An Event, Not a Conference<\/a>: AHA requires both mental energy \u2014 science to be learned, posters to be read, and a program book the size of an encyclopedia to maneuver through \u2014 and physical energy \u2014 to hike to the various sessions spread all over this large conference center.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/mi-free-a-free-lunch-for-patients-and-insurers-alike\/\">MI FREE: A Free Lunch for Patients and Insurers Alike?<\/a> Removing copays increased adherence, decreased events, and saved the sponsoring insurance company a tidy sum. So are the issues with insurance-sponsored studies different from those with pharmaceutical-sponsored ones?<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/go-red-highlights-from-the-women-and-heart-disease-session\/\">Go Red: Highlights from the Women and Heart Disease Session:<\/a> Fascinating data on clinical and psychosocial aspects of heart disease in women.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/my-first-oral-presentation-life-on-the-other-side-of-the-podium\/\">My First Oral Presentation: Life on the Other Side of the Podium<\/a>: Not having to drag around a poster container was refreshing, but instead, this oral presenter was dragging around his dread.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/finding-wisdom-in-unfamiliar-ways-in-a-familiar-place\/\">Finding Wisdom in Unfamiliar Ways in a Familiar Place<\/a>: The Scientific Sessions are not the only way to learn at AHA.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/what%e2%80%99s-up-interventionally\/\">What\u2019s Up, Interventionally?<\/a> The latest in coronary intervention, including angiography for erectile dysfunction.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/global-cv-health-concerns-macro-and-micro\/\">Global CV Health Concerns: Macro and Micro<\/a>: Now I know how to approach a potential mentor. But will it really take at least 10 years to train in research?<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/stenosis-vs-stroke-is-treatment-worth-the-risk\/\">Stenosis vs. Stroke: Is Treatment Worth the Risk?<\/a> As a future interventional cardiologist and the grandson of someone who has suffered a debilitating stroke, a discussion of the PARTNER B trial results and TAVI really hit home for Jahangir.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/%e2%80%9cthe-center-where-it-all-happens%e2%80%9d\/\">\u201cThe Center Where It All Happens\u201d<\/a>: This is the first AHA meeting for this participant who is deep in the trenches of her first year of fellowship.<\/li>\n<\/ul>\n<ul>\n<li><a class=\"home-act-title\" href=\"..\/fellowship-training\/what-will-keep-me-coming-back-to-aha\/\">What Will Keep Me Coming Back to AHA?<\/a>\u00a0 AHA attendance is on the decline, however, Ryan keeps coming back because of special seminars that delve into the heart of what he&#8217;s researching.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/epcot-for-foodie-cardiologists\/\">Epcot for Foodie Cardiologists: <\/a>Epcot\u2019s survey of food from around the world sure beats this fellow\u2019s memories of astronaut ice cream at Disney theme parks.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/an-unexpected-preconference-overload\/\">An Unexpected Preconference Overload:<\/a> Anyone else surprised by the volume of ad-driven snail mail and email \u2013 most of it junk \u2013 we all got in the run up to the conference?<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/part-of-the-system\/\">Part of the System:<\/a> From AHA novice to conference veteran.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/aha-11-how-does-one-choose-what-to-do\/\">AHA.11: How Does One Choose What to Do?<\/a> How I&#8217;ll make choices among the dizzying array of options for how to spend time at the AHA conference.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/aha-11-an-orlando-eating-tour\/\">AHA.11: An Orlando Eating Tour:<\/a> A guide to restaurants while you&#8217;re in Orlando.<\/li>\n<\/ul>\n<p><strong><br \/>\n<\/strong><strong>PREVIEWS<\/strong><\/p>\n<ul>\n<li><a href=\"..\/news\/the-aha-in-orlando-a-preview\/\">The AHA in Orlando: A Preview:<\/a> AHA Scientific Sessions Program Chair Elliott Antman provides CardioExchange with a preview of the many expected highlights of the meeting.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/whats-this-fellow-looking-forward-to-at-aha\/\">What&#8217;s This Fellow Looking Forward to at AHA?<\/a> John Ryan discusses the studies he\u2019s most looking forward to checking out at AHA this year.<\/li>\n<\/ul>\n<ul>\n<li><a href=\"..\/fellowship-training\/how-to-prep-for-aha-an-expert%e2%80%99s-advice-for-fellows\/\">How to Prep for AHA: An Expert\u2019s Advice for Fellows:<\/a> Dr. Thomas Ryan explains how fellows can get the most from the AHA Scientific Sessions, both as attendees and as presenters.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Whether you were in Orlando for AHA.11 or not, you&#8217;ll want to check out our coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting. VIEWS AND ANALYSIS ROUNDTABLE: After SATURN, What Role for Rosuvastatin? A CardioExchange Panel: [&hellip;]<\/p>\n","protected":false},"author":343,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-13244","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/13244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/343"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=13244"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/13244\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=13244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=13244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=13244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}